Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCNT-hES-RPE Cells in Advanced Dry AMD
NCT03305029Phase 1Unknown
- Sponsor
- CHA University
- Start
- May 2016
- Primary completion
- Apr 2019
- Modality
- Patient-derived iPSCs, Allogeneic iPSCs
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of scnt-hes-rpe in age-related macular degeneration (AMD), sponsored by CHA University. Primary endpoint: Safety of SCNT-hES-RPE cells at 60 months. Status: unknown.
02
Drugs
scnt-hes-rpe
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on NCT03305029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03305029.